Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow

Jun 14, 2023

Feature 1

Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow
Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow

MGI: Pioneering Life Science Innovation Through ESHG Partnerships

Strengthening RNA Sequencing Protocols with Alithea Genomics Collaboration

MGI: Pioneering Life Science Innovation Through ESHG Partnerships Strengthening RNA Sequencing Protocols with Alithea Genomics Collaboration Glasgow, UK, 14 June 2023 – MGI Tech Co., Ltd. ("MGI"), a global leader in life science technology, unveiled significant partnerships at the ESHG Conference in Glasgow. These collaborations underscore MGI's strategic focus on the European life sciences market and its dedication to advancing innovation in sequencing and automation technologies.

MGI: A Leading Supplier of Gene Sequencing Platforms

During the Corporate Satellite meeting, MGI, renowned for its gene sequencing platforms and sample preparation systems, announced its partnership with Sistemas Genomicos. Alejandra Pérez presented impressive results of the CE-IVD Whole Exome Sequencing solution on the MGI platform. Nik Matthews, a respected scientific expert from Imperial College London, provided insights into the workflow of the new NEB library preparation solution for MGI, highlighting its benefits for DNBSEQ users. Prof. Yannis Pitsiladis presented his multi-omic approach to combating drug abuse in sports using the DNBSEQ platform, emphasizing its potential and versatility.

MGI's Commitment to Life Science Innovation

"We are excited to showcase our latest achievements at the ESHG Conference, reflecting significant advancements in life science innovation. These partnerships and collaborations exemplify MGI's commitment to driving scientific progress and transforming healthcare,” stated Dr. Yong Hou, General Manager of MGI Europe and Africa.

"By leveraging cutting-edge technologies and fostering collaborations, we aim to revolutionize genomics research, empower scientists and clinical labs with state-of-the-art solutions. This reaffirms MGI's position as a leader in the industry and highlights our dedication to pushing the boundaries of what is possible in the field of life sciences."

MGI and Alithea Genomics: A Strategic Partnership

In line with MGI's commitment to innovation in RNA sequencing, the company also signed a strategic partnership with Alithea Genomics. This Swiss company, known for challenging the status quo in bulk RNA sequencing, has developed extraction-free and massively multiplexed RNA-seq library preparation solutions with native MGI compatibility.

The event attracted a diverse audience of researchers, both in person and online, along with senior management members from MGI. The platform provided MGI with a great opportunity to strengthen its commitment to enhancing innovation through local partnerships in Europe, a market MGI considers to be a key one because of its world-class academic and public research funding, extensive regulatory landscape, and wide range of clinical applications.

For more information about MGI, please visit: MGI Tech

Note: Availability of StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents may vary by region. Products are provided for Research Use Only. Not for use in diagnostic procedures (except as specifically noted).

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

RNA SEQUENCING

MGI TECH CO., LTD.

ESHG CONFERENCE

LIFE SCIENCE INNOVATION

GENOMICS RESEARCH

Share

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer
Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

Mar 4, 2024

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

MGI Tech has joined forces with Eurofins Genomics Europe Genotyping A/S, marking a pivotal moment in the advancement of large-scale genomic projects. This partnership heralds the first corporate order of the DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in Europe.

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding
Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Nov 10, 2023

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Latvia MGI Tech SIA advances DNA methylation research with significant European funding, achieving groundbreaking progress in biotechnology and innovation.

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment
MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Jul 10, 2023

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Explore MGI's latest achievement as its DNBSEQ-T20×2 gene sequencing platform wins the prestigious Globee® for Medical Equipment in the 15th Annual 2023 Golden Bridge Business and Innovation Awards®. This post highlights MGI's commitment to innovation in the life science industry, their groundbreaking T20 gene sequencer, and how their technology is reshaping healthcare outcomes and the genetic industry.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.